Home / Health / Galderma Unveils Dermatology Innovations at EADV 2026
Galderma Unveils Dermatology Innovations at EADV 2026
23 Sep
Summary
- Galderma will present 19 abstracts at the 2026 EADV Congress.
- New data will cover chronic inflammatory diseases and skin longevity.
- Innovations in acne management will also be showcased.
Galderma will showcase its commitment to advancing dermatology at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, with 19 abstracts and a comprehensive scientific education program. The company aims to deepen understanding of biological and quality-of-life factors, driving innovation in targeted treatments, skin longevity, and evidence-based care.
Key presentations will focus on chronic inflammatory skin diseases, including new data on atopic dermatitis and prurigo nodularis. This includes long-term safety and efficacy data for Nemluvio, exploring its impact on sleep disturbance and quality of life. A symposium will also target IL-31 neuroimmune pathways.
Further research will delve into sensitive skin and skin longevity, examining cellular senescence and its role in skin aging. Galderma will present findings on Cetaphil products for barrier restoration and anti-aging benefits, alongside discussions on dermatoporosis and preserving skin health over time.
The congress will also feature innovations in acne management, with research on anti-inflammatory properties of new combinations and the efficacy of Aklief. Galderma's participation underscores its dedication to addressing unmet needs across the full spectrum of dermatology.
